Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Ritt

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
EJNMMI Physics|August 27, 2025
Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imagingFrida Westerbergh, Lisa McDougall, Philipp Ritt, et al.
Clinical Nuclear Medicine|October 25, 2016
First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate CancerJulia Reinfelder, Torsten Kuwert, Michael Beck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2012
Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CTMarco Wiesmüller, Harald H Quick, Bharath Navalpakkam, et al.
Journal of Clinical Medicine|June 13, 2020
DSC Brain Perfusion Using Advanced Deconvolution Models in the Diagnostic Work-up of Dementia and Mild Cognitive Impairment: A Semiquantitative Comparison with HMPAO-SPECT-Brain PerfusionManuel A Schmidt, Tobias Engelhorn, Stefan Lang, et al.
Clinical Nuclear Medicine|February 6, 2018
SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate CancerChristian Schmidkonz, Michael Cordes, Michael Beck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 7, 2025
Safety and efficacy of [<sup>177</sup>Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancerRené Fernández, Cristian Soza-Ried, Vasko Kramer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 2, 2025
Biodistribution and dosimetry of [<sup>177</sup>Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancerPhilipp Ritt, René Fernández, Cristian Soza-Ried, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 5, 2018
<sup>68</sup>Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancerChristian Schmidkonz, Michael Cordes, Daniela Schmidt, et al.
Zeitschrift Fur Medizinische Physik|May 11, 2026
Applications of artificial intelligence in nuclear medicineLena Kaiser, Thomas Wendler, Deni Hardiansyah, et al.
Clinical Nuclear Medicine|June 20, 2018
Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate CancerChristian Schmidkonz, Michael Cordes, Michael Beck, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
EJNMMI Physics|August 27, 2025
Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imagingFrida Westerbergh, Lisa McDougall, Philipp Ritt, et al.
Clinical Nuclear Medicine|October 25, 2016
First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate CancerJulia Reinfelder, Torsten Kuwert, Michael Beck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2012
Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CTMarco Wiesmüller, Harald H Quick, Bharath Navalpakkam, et al.
Journal of Clinical Medicine|June 13, 2020
DSC Brain Perfusion Using Advanced Deconvolution Models in the Diagnostic Work-up of Dementia and Mild Cognitive Impairment: A Semiquantitative Comparison with HMPAO-SPECT-Brain PerfusionManuel A Schmidt, Tobias Engelhorn, Stefan Lang, et al.
Clinical Nuclear Medicine|February 6, 2018
SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate CancerChristian Schmidkonz, Michael Cordes, Michael Beck, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 7, 2025
Safety and efficacy of [<sup>177</sup>Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancerRené Fernández, Cristian Soza-Ried, Vasko Kramer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 2, 2025
Biodistribution and dosimetry of [<sup>177</sup>Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancerPhilipp Ritt, René Fernández, Cristian Soza-Ried, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 5, 2018
<sup>68</sup>Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancerChristian Schmidkonz, Michael Cordes, Daniela Schmidt, et al.
Zeitschrift Fur Medizinische Physik|May 11, 2026
Applications of artificial intelligence in nuclear medicineLena Kaiser, Thomas Wendler, Deni Hardiansyah, et al.
Clinical Nuclear Medicine|June 20, 2018
Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate CancerChristian Schmidkonz, Michael Cordes, Michael Beck, et al.
Pageof 5